by Clinical Neuropsychologist Online | Monday, September 28, 2026 | Dementia
Abstract INTRODUCTION Dysregulated cholesterol metabolism represents a critical metabolic stressor in the central nervous system, contributing to neuronal injury across multiple neurological conditions, including Alzheimer’s disease (AD). While glucagon-like...
by Clinical Neuropsychologist Online | Monday, September 28, 2026 | Dementia
Abstract Since the groundbreaking work of Alois Alzheimer in the early 1900s, Alzheimer’s disease research has evolved immensely, most notably with the establishment of the Alzheimer’s Disease Research Centers (ADRC). Fueled by the vision and funding of...
by Clinical Neuropsychologist Online | Monday, September 28, 2026 | Dementia
Abstract INTRODUCTION Plasma phosphorylated tau 217 (p‑tau217) immunoassays are increasingly being used to assess Alzheimer’s disease (AD) pathology despite limited data affirming test reliability over time. METHODS Clinical performance of the Fujirebio...
by Clinical Neuropsychologist Online | Monday, September 28, 2026 | Dementia
Abstract INTRODUCTION Exposure to aerosolized pollutants is a risk factor for cognitive impairment and dementia, but the specific features of exposure-related neurodegeneration remain unclear. METHODS We measured the World Trade Center Neurotoxicant Exposure Severity...
by Clinical Neuropsychologist Online | Monday, September 28, 2026 | Dementia
Abstract INTRODUCTION We tested whether combining Alzheimer’s disease and related dementias (ADRD) polygenic risk scores (PRS) with biological aging markers improves ADRD risk prediction. METHODS In 16,215 UK Biobank (UKB) participants free of ADRD at baseline...
